N/A N=30 Evaluation of Wear Experience With a Water Surface Daily Disposable Contact Lens
Contact Lens
Primary: Subjective Assessment of Overall Comfort With Verofilcon A Daily Disposable Lenses for Astigmatism — 91 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Regional Block for Postoperative Free Flap Care
Pain Management
Primary: Opioid Utilization Measured in Oral Morphine Equivalent (OME) — 118; 166 mg
Phase 3 N=1,988 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 25.5; 24.6; 21.5; 22.3 Percentage of participants
Phase 2 N=83 Gulf War Illness Inflammation Reduction Trial
Chronic Inflammation · Chronic Pain · Fatigue
Primary: Change From Baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) Scores at 8 and 16 Weeks — 40.8; 41.5; 43.5; 43.4 units on a scale
Phase 2 N=21 High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
GVHD
Primary: Percentage of Participants Who Experience Acute GvHD — 38.46 percentage of participants
Phase 2 N=40 Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Multiple Myeloma
Primary: 4 Cycle Response Rate — 0.971 proportion of participants
Phase 2 N=381 A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Hypercholesterolemia · Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8 — -40.0; -54.5; -57.9; -59.7 Percentage Change — p=<0.001
Phase 2 N=29 Depressed Mood Improvement Through Nicotine Dosing 2
Depressive Disorder
Primary: MADRS (Montgomery Asberg Depression Rating Scale) Score Change — -15.4 units on a scale — p=< 0.001
Phase 2 N=124 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
Solid Tumor · Metastatic Bladder Cancer
Primary: Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
Phase 4 N=52 Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 51.98; 79.37; 61.95; 61.39 Score on a scale — p=<0.0001
Phase 3 N=211 The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Amyloidosis
Primary: Percentage of Participants With Adverse Events (AEs) Leading to Study Discontinuation — 49.0; 16.8; 0.0 percentage of participants
Phase 2 N=104 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Lymphoma, Non-Hodgkin · Lymphoma · Lymphoma, B-Cell
Primary: Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3 — 0.0 Percentage of participants
Phase 2 N=350 Study of BHV-4157 in Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 48 — 6.7; 6.7 units on a scale — p=0.9809
Phase 2 N=114 Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485
Phase 1 N=8 Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
HIV Infections
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254 — 102400 Hours*nanograms per milliliter